Most Read Articles
01 Jan 2015
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.
26 Aug 2017
Elderly individuals with high levels of serum uric acid may be at an increased risk of dementia, particularly vascular or mixed dementia, a study suggests.
Dr. Joseph Delano Fule Robles, 01 Mar 2017

The tau and Aβ amyloid pathways have emerged as possible novel targets in treating Alzheimer’s disease (AD), according to studies discussed at the recently concluded Hong Kong Pharmacy Conference.

DHA, DPA levels associated with lower ischaemic stroke risk

13 Oct 2017

Higher circulating levels of docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) appear to be protective against incident atherothrombotic and cardioembolic strokes, respectively, according to a recent study.

Researchers measured data on baseline circulating phospholipid fatty acids from three separate US cohorts: CHS (Cardiovascular Health Study), NHS (Nurses’ Health Study) and HPFS (Health Professionals Follow-Up Study). They categorized the outcome of ischaemic strokes as atherothrombotic (large- and small-vessel infarctions) or cardioembolic.

During a median follow-up of 11.2 (CHS) and 8.3 years (pooled, NHS and HPFS), a total of 953 incident ischaemic strokes were reported. Of these, 408 were atherothrombotic, 256 were cardioembolic and 289 were of undetermined subtypes.

Multivariable Cox proportional hazards analysis found the risk of total ischaemic stroke to be lower with higher levels of DPA (highest vs lowest quartiles; pooled hazard ratio [HR], 0.74; 95 percent CI, 0.58 to 0.92) and DHA (pooled HR, 0.80; 0.64 to 1.00) but not eicosapentaenoic acid (pooled HR, 0.94; 0.77 to 1.19).

Specifically, higher DHA was protective against the risk of atherothrombotic stroke (HR, 0.53; 0.34 to 0.83), while higher DPA was associated with lower cardioembolic stroke risk (HR, 0.58; 0.37 to 0.92).

Researchers noted that the findings in each individual cohort were consistent with pooled results.

“[The] findings [also] suggest differential pathways of benefit for DHA, DPA and eicosapentaenoic acid,” they said.

The protective effect of DHA and DPA against ischaemic stroke has been previously investigated. Available evidence shows that accumulation of DHA in the brain may reduce neuroinflammation and activation of antiapoptotic pathways. [J Biol Chem 2003;278:43807–43817]

Meanwhile, DPA, along with other long-chain n-3 polyunsaturated fatty acids, has been reported to prevent arrhythmia and reduce the onset of atrial fibrillation by directly influencing atrial and ventricular myocyte electrophysiology, as well as modulations in autonomic tone. Another potential mechanism is an anti-inflammatory or antifibrotic effect. [J Am Coll Cardiol 2011;58:2047–2067]

Editor's Recommendations
Most Read Articles
01 Jan 2015
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.
26 Aug 2017
Elderly individuals with high levels of serum uric acid may be at an increased risk of dementia, particularly vascular or mixed dementia, a study suggests.
Dr. Joseph Delano Fule Robles, 01 Mar 2017

The tau and Aβ amyloid pathways have emerged as possible novel targets in treating Alzheimer’s disease (AD), according to studies discussed at the recently concluded Hong Kong Pharmacy Conference.